ALZN Financials

Income Statement
MetricQ4 2026Q3 2026Q2 2026Q1 2026Q4 2025
Revenue
0
0
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
0
0
0
Operating Expenses
2.9M
+30.6%
2.2M
+120.2%
998.1K
-63.0%
2.7M
+137.1%
1.1M
R&D
434.0K
-66.1%
1.3M
+625.3%
176.3K
-89.9%
1.7M
+286.7%
450.2K
SG&A
2.4M
+165.2%
919.0K
+11.8%
821.8K
-14.3%
959.3K
+39.3%
688.8K
Operating Income
-2870877
-30.6%
-2197654
-120.2%
-998109
+63.0%
-2700201
-137.1%
-1138936
EBITDA
-2843192
-31.0%
-2169969
-123.6%
-970424
+63.7%
-2672516
-137.3%
-1126251
Net Income
-2869949
-30.5%
-2198991
-119.7%
-1000758
+63.0%
-2702684
-137.2%
-1139445
EPS (Basic)
$-0.71
-22.4%
$-0.58
-93.3%
$-0.30
+76.6%
$-1.28
EPS (Diluted)
$-0.71
-22.4%
$-0.58
-93.3%
$-0.30
+76.6%
$-1.28
Shares (Diluted)
4.1M
+6.6%
3.8M
+12.5%
3.4M
+60.5%
2.1M
Alzamend Neuro (ALZN) — Financials